Atezolizumab-Based Combination Therapy for Prostate Cancer
Trial Summary
What is the purpose of this trial?
This phase II trial studies how well atezolizumab works alone or in combination with etrumadenant or tocilizumab in treating men with localized prostate cancer before radical prostatectomy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Androgens can cause the growth of prostate cancer cells. IL-6 is expressed by prostate cancer and within the tumor microenvironment and shown to enhance prostate cancer and disease progression. Treatment with an anti-IL-6 antibody such as tocilizumab may inhibit cancer progression. Giving atezolizumab in combination with etrumadenant or tocilizumab may work better in treating prostate cancer.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop all current medications. However, if you are on finasteride or dutasteride, you must stop and have a 6-week washout period before joining. Also, if you are on certain medications like strong CYP3A4 inducers or inhibitors, you may need to stop them before starting the trial. It's best to discuss your specific medications with the trial team.
What data supports the idea that Atezolizumab-Based Combination Therapy for Prostate Cancer is an effective treatment?
The available research shows mixed results for Atezolizumab-Based Combination Therapy in treating prostate cancer. One study found that adding atezolizumab to enzalutamide did not improve survival in patients with metastatic prostate cancer. However, another study indicated that combining cabozantinib with atezolizumab showed promising results for patients with metastatic castration-resistant prostate cancer, especially those who had limited options after other treatments. This suggests that while the therapy may not be effective for all patients, it could be beneficial for certain groups, particularly when combined with other drugs like cabozantinib.12345
What safety data is available for Atezolizumab-based therapy?
Atezolizumab, also known as Tecentriq, has been evaluated for safety in various clinical trials. It has been approved by the FDA for use in urothelial carcinoma and non-small cell lung cancer. The toxicity profile of Atezolizumab is considered favorable, with manageable safety in patients with advanced bladder cancer and non-small-cell lung cancer. In trials, treatment-related toxicities were reported in 66% of patients, with 7-12% experiencing grade 3-4 adverse events. Overall, Atezolizumab has shown a manageable safety profile in patients with metastatic urothelial carcinoma and other cancers.678910
Is the drug Atezolizumab, Etrumadenant, Tocilizumab a promising treatment for prostate cancer?
Atezolizumab, known as Tecentriq, is a drug that has shown promise in treating various cancers by boosting the body's immune response against tumors. It has been approved for use in bladder and lung cancers, and studies suggest it could be effective when combined with other treatments. This makes it a promising option for further research in treating prostate cancer.678911
Research Team
David Y Oh, MD, PhD
Principal Investigator
University of California, San Francisco
Eligibility Criteria
Men with localized prostate cancer who haven't had previous treatments for it, are over 18, in good health with proper organ and marrow function, and eligible for surgery. They must have high-risk disease for certain parts of the trial, a testosterone level above 150 ng/dL, agree to use contraception and not donate sperm.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Atezolizumab (Monoclonal Antibodies)
- Etrumadenant (Other)
- Tocilizumab (Monoclonal Antibodies)
Find a Clinic Near You
Who Is Running the Clinical Trial?
David Oh
Lead Sponsor
Lawrence Fong
Lead Sponsor
Genentech, Inc.
Industry Sponsor